|
Sep 1, 2012
By:
Bill Trombetta
Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.
|
|
Sep 1, 2011
By:
Bill Trombetta
Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.
|
|
Sep 1, 2010
By:
William Looney, Bill Trombetta
Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond
|
|
Sep 1, 2009
By:
Bill Trombetta
Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27."
|
Sep 1, 2008
By:
Bill Trombetta
Pharm Exec's 7th annual review of the top companies. We slice and dice the numbers to see who's the best a what. (pdf)
|
Jun 1, 2008
By:
Bill Trombetta
Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?
|
Our sixth annual report dives deep into the numbers to discover the industry's true top performers—and how the cookie really crumbles
Sep 1, 2007
By:
Bill Trombetta
For the sixth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph’s University to analyze the pharma industry's financial performance with a battery of business metrics, old and new. The highlights: Genentech pulls ahead of its longtime rival, Amgen. Forest delivers another strong performance, despite dropping revenue. Schering-Plough is building enterprise value. Biogen Idec racks up a stellar profit margin. And Merck? Well, Merck is back, baby. And the winner is…
|
|
Apr 1, 2007
By:
Bill Trombetta
Ever wonder how all those biotechs, specialty shops, and generics that make up Not Big Pharma ever manage to stay in business? Pharm Exec asked Bill Trombetta of St. Joseph's University to look at their books, analyzing their financial performance with the same metrics he uses for our annual Industry Audit. His findings may surprise you. In fact, when you check the bottom line, you just might consider changing teams.
|
|
The Company of the Year: Our fifth annual report dives deep into the numbers and comes up with the industry's true top performers.
Sep 1, 2006
By:
Bill Trombetta
For the fifth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph's University to analyze the pharma industry's financial performance with a battery of business metrics old and new. The highlights: Two top biotechs race neck-and-neck for first place, Forest delivers another strong performance, and AstraZeneca squeezes past Johnson & Johnson and GlaxoSmithKline into the top four for the first time ever. And the winner is . . .
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
